It Seems ICU Medical, Inc. (ICUI) Will Go Up. Just Reaches 52-Week High

March 13, 2018 - By Hazel Jackson

Investors sentiment decreased to 0.86 in 2017 Q3. Its down 0.20, from 1.06 in 2017Q2. It fall, as 23 investors sold ICU Medical, Inc. shares while 74 reduced holdings. 30 funds opened positions while 53 raised stakes. 15.58 million shares or 0.61% more from 15.48 million shares in 2017Q2 were reported.
Martingale Asset Lp invested in 0.1% or 38,103 shares. 6,100 were accumulated by Louisiana State Employees Retirement Systems. Susquehanna Intll Group Limited Liability Partnership owns 10,455 shares. Eagle Boston Investment stated it has 1,065 shares or 0.02% of all its holdings. Elk Creek Prtn Ltd Limited Liability Company reported 2.2% stake. Amalgamated Bank & Trust invested in 0.01% or 2,053 shares. Tiaa Cref Inv Mgmt Limited Liability holds 0.01% of its portfolio in ICU Medical, Inc. (NASDAQ:ICUI) for 39,703 shares. State Of Alaska Department Of Revenue has invested 0.03% in ICU Medical, Inc. (NASDAQ:ICUI). American International holds 0.01% or 11,906 shares. Barrett Asset Management Ltd Liability Corp accumulated 6,375 shares. 29,665 are owned by Qs Investors Ltd Company. Comml Bank Of New York Mellon Corp holds 0.01% of its portfolio in ICU Medical, Inc. (NASDAQ:ICUI) for 182,715 shares. Oppenheimer Asset reported 0.04% of its portfolio in ICU Medical, Inc. (NASDAQ:ICUI). Sector Pension Investment Board reported 9,443 shares. California Pub Employees Retirement Sys accumulated 28,342 shares or 0.01% of the stock.

Since September 15, 2017, it had 0 buys, and 6 sales for $26.16 million activity. Jain Vivek sold $420,950 worth of stock or 2,205 shares. Lamb Scott E sold $5.20M worth of stock or 23,624 shares. The insider SAUCEDO JOSEPH R sold $1.71 million.

The stock of ICU Medical, Inc. (NASDAQ:ICUI) hit a new 52-week high and has $272.10 target or 6.00 % above today’s $256.70 share price. The 7 months bullish chart indicates low risk for the $5.08B company. The 1-year high was reported on Mar, 13 by If the $272.10 price target is reached, the company will be worth $304.98M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 1.46% or $3.8 during the last trading session, reaching $256.7. About 38,455 shares traded. ICU Medical, Inc. (NASDAQ:ICUI) has risen 61.84% since March 13, 2017 and is uptrending. It has outperformed by 45.14% the S&P500.

ICU Medical, Inc. (NASDAQ:ICUI) Ratings Coverage

Among 5 analysts covering ICU Medical (NASDAQ:ICUI), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. ICU Medical had 11 analyst reports since August 11, 2015 according to SRatingsIntel. The company was maintained on Tuesday, August 11 by Roth Capital. The company was maintained on Wednesday, August 9 by Roth Capital. The stock of ICU Medical, Inc. (NASDAQ:ICUI) has “Buy” rating given on Friday, November 6 by Roth Capital. The firm earned “Buy” rating on Friday, March 11 by Gabelli. The stock of ICU Medical, Inc. (NASDAQ:ICUI) has “Buy” rating given on Friday, August 11 by Gabelli. The company was maintained on Tuesday, August 11 by TH Capital. The firm has “Buy” rating given on Friday, November 6 by TH Capital. The rating was maintained by Piper Jaffray on Tuesday, August 11 with “Overweight”. Zacks upgraded ICU Medical, Inc. (NASDAQ:ICUI) on Monday, August 17 to “Hold” rating.

More recent ICU Medical, Inc. (NASDAQ:ICUI) news were published by: which released: “ICU Medical’s (ICUI) CEO Vivek Jain on Q3 2017 Results – Earnings Call Transcript” on November 11, 2017. Also published the news titled: “3 Stocks to Watch on Friday: ICU Medical, Incorporated (ICUI), Keysight …” on March 02, 2018.‘s news article titled: “ICU Medical Inc.” with publication date: January 09, 2017 was also an interesting one.

ICU Medical, Inc. develops, manufactures, and sells medical devices used in infusion therapy, critical care, and oncology applications worldwide. The company has market cap of $5.08 billion. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patientÂ’s vein for use in hospitals and ambulatory clinics. It has a 178.51 P/E ratio. The companyÂ’s infusion therapy products include needlefree connector products, such as MicroClave and MicroClave Clear, Neutron, NanoClave, Clave, and SwabCap; custom infusion sets; and Tego needlefree hemodialysis connectors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: